KRAS and pancreatic adenocarcinoma: KRAS mutations occur most frequently in pancreatic adenocarcinoma (PAAD, ~90%) [2], followed by colorectal cancer (CRC, 36–40%) [3], cholangiocarcinoma (CHOL, ~27%) [4], and lung adenocarcinoma (LUAD, 15–20%) [5].